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Summary
 
Chlamydia trachomatis
 
, an obligate intracellular bacterial pathogen of mucosal surfaces, is a major
cause of preventable blindness and sexually transmitted diseases for which vaccines are badly
needed. Despite considerable effort, antichlamydial vaccines have proven to be elusive using
conventional immunization strategies. We report the use of murine bone marrow–derived
dendritic cells (DC) pulsed ex vivo with killed chlamydiae as a novel approach to vaccination
against chlamydial infection. Our results show that DC efficiently phagocytose chlamydiae, se-
 
crete IL-12 p40, and present chlamydial antigen(s) to infection sensitized CD4
 
1
 
 T cells. Mice
immunized intravenously with chlamydial-pulsed DC produce protective immunity against
chlamydial infection of the female genital tract equal to that obtained after infection with live
 
organisms. Immunized mice shed 
 
z
 
3 logs fewer infectious chlamydiae and are protected from
genital tract inflammatory and obstructive disease. Protective immunity is correlated with a
chlamydial-specific Th1-biased response that closely mimics the immune response produced
after chlamydial infection. Thus, ex vivo antigen-pulsed DC represent a powerful tool for the
study of protective immunity to chlamydial mucosal infection and for the identification of
chlamydial protective antigens through reconstitution experiments. Moreover, these findings
might impact the design of vaccine strategies against other medically important sexually trans-
mitted diseases for which vaccines are sought but which have proven difficult to develop.
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C
 
hlamydia trachomatis
 
 is an obligate intracellular epithe-
liotropic bacterium with a unique biphasic intracellu-
 
lar life cycle (1). 
 
C
 
.
 
 trachomatis
 
 infection of the conjunctival
epithelium causes trachoma, the world’s leading cause of
preventable blindness (2). Infection of the genitourinary
tract of humans with 
 
C
 
.
 
 trachomatis
 
 is a major cause of sexu-
ally transmitted diseases (STD).
 
1
 
 Genital infection of women
constitutes a significant risk since sequelae often lead to pel-
vic inflammatory disease, ectopic pregnancy, or reproduc-
tive disability (3–6). Immunotherapy is believed to be the
most promising and effective strategy for controlling these
medically important diseases; however, despite years of ef-
fort, an efficacious vaccine does not exist.
The lack of progress towards the development of a
chlamydial vaccine has been in part due to an incomplete
understanding of host immune mechanisms that mediate
protective immunity against infection of the genital mucosa.
The mouse model of 
 
C
 
.
 
 trachomatis
 
 infection of the female
genital tract mimics human infection (7–10) and is there-
fore a useful preclinical model for the study of adaptive immu-
nity to infection and vaccine development. The availability
of gene knockout mice with targeted immune deficiencies
has made the mouse model very useful for the study of im-
munity to chlamydial infection. Collectively, infection of
knockout mice (11, 12) and adoptive immunization using
polyclonal T cell subsets (13), or T cell clones (14) provide
compelling evidence that MHC class II–restricted CD4
 
1
 
 T
cell responses are central to the development of adaptive
protective immunity to chlamydial infection of the female
genital tract. Protective immunity, defined by accelerated
clearance of epithelial infection and reduction in cervico-
 
1
 
Abbreviations used in this paper:
 
 DC, dendritic cells; EB, elementary body;
HK, heat killed; IFU; inclusion forming unit; MoPn, mouse pneumonitis;
STD, sexually transmitted disease.
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vaginal shedding of infectious organisms, is mediated by an
IL-12–dependent T helper type 1 immune response (15,
16). Antibodies, either humoral or local (11, 17–19) and
CD8
 
1
 
 T cells (11, 12) play subordinate roles in chlamydial
clearance from the murine genital tract. Despite this
knowledge, it has not been straightforward in practice to
develop conventional vaccines that target protective anti-
chlamydial CD4
 
1
 
 Th1-mediated immunity at the genital
mucosa. To date, immunization that provides optimum
protective immunity against chlamydial infection of the
genital tract has been achieved only by using viable
chlamydiae (20, 21) a finding that has led investigators to
conclude that effective vaccination against chlamydiae will
require the use of live-attenuated chlamydial organisms.
Genetic systems for chlamydiae are not available and are
difficult to develop, therefore it is unlikely that a safe and
efficacious live attenuated chlamydial vaccine will be forth-
coming in the near future.
Dendritic cells (DC) are potent professional APC that
play a central role in the induction of T cell immunity in
vivo (22, 23). Large numbers of DC with powerful in vivo
antigen presenting properties can be propagated in vitro us-
ing recombinant cytokines (24). It is well documented that
ex vivo antigen-pulsed DC are effective inducers of tumor-
specific protective immunity (25–31). The utility of ex
vivo antigen-pulsed DC as an alternative approach towards
the development of new immunotherapies against infec-
tious agents has not been extensively studied (22). In this
report we show that adoptively transferred DC pulsed ex
vivo with nonviable chlamydial organisms are potent in-
ducers of chlamydial-specific CD4
 
1
 
 Th1 immune re-
sponses that elicit levels of protective immunity against
chlamydial genital tract challenge equal to that obtained af-
ter infection with live chlamydial organisms. Our findings
offer encouragement for the future development of an effi-
cacious vaccine against 
 
C
 
.
 
 trachomatis
 
 diseases of humans
and perhaps other infectious agents for which vaccines are
sought after but have not been forthcoming.
 
Materials and Methods
 
Chlamydiae and Mice.
 
The mouse pneumonitis strain of 
 
C
 
.
 
trachomatis
 
 (MoPn) was grown in HeLa 229 cells. Infectious ele-
mentary bodies (EB) were purified by density gradient centrifuga-
tion and infectious forming units (IFU) were determined as pre-
viously described (32). Chlamydial EB were heat killed (HK) by
incubation at 56
 
8
 
C for 30 min. Heat-treated EB inoculated onto
monolayers of HeLa 229 cells did not yield recoverable IFU (data
not shown). After heat inactivation of chlamydiae the number of
IFU in purified stock preparations was used to calculate the ratio
of chlamydiae incubated with DC. Female C57BL/10 (H-2
 
b
 
)
mice were purchased from Jackson Laboratory (Bar Harbor, ME)
and used between 8 and 12 wk of age. Animals were housed in an
Association for Assessment and Accreditation of Laboratory Ani-
mal Care-accredited facility in filter top cages under standard en-
vironmental conditions and provided food and water ad libitum.
 
Dendritic Cell Cultures.
 
Bone marrow–derived dendritic cells
were prepared as described (24, 33). In brief, 2 
 
3
 
 10
 
7
 
 bone mar-
row cells were cultured in IMDM (GIBCO BRL, Gaithersburg,
 
MD) supplemented with 10% FCS, 50 
 
m
 
M 2-ME, 10 
 
m
 
g/ml
gentamicin sulfate, 10 ng/ml murine GM-CSF, and 1 
 
3
 
 10
 
3
 
 U/ml
IL-4 (PharMingen, San Diego, CA). On day 3 of culture, nonad-
herent cells were removed and fresh medium containing GM-
CSF and IL-4 was added. On day 5 of culture, DC were isolated
by transferring nonadherent cells to new culture plates and incu-
bating at 37
 
8
 
C for at least 2 h. This was repeated once to remove
contaminating macrophages. The purity of DC was assessed by
FACS
 
Ò
 
 analysis after staining with anti-I-A
 
b
 
, N418 and B220
mAbs. Consistent with other reports (24, 33), between 80 and
90% of the cells showed uniformly high levels of MHC class II
expression, low level CD11C 
 
a
 
x
 
b
 
2
 
-integrin (N418) staining, and
negative staining for B220.
 
Fluorescent Antibody Staining and Electron Microscopy.
 
DC were
resuspended in IMDM and mixed with HK chlamydial EB at a
ratio of 1:50, respectively. The mixture was incubated at 37
 
8
 
C for
1.5 h with periodic mixing. DC were washed, resuspended in
IMDM-10, added to 24-well plates containing coverslips and in-
cubated at 37
 
8
 
C for 24 h. The cells were then fixed with absolute
methanol and stained with mAb EVI-H1 specific to chlamydial
LPS followed by FITC-labeled goat anti–mouse IgG. For elec-
tron microscopy, chlamydial inoculated DC were harvested by
gentle scraping and fixed in 2.5% glutaraldehyde/4% paraformal-
dehyde in 0.1 M sodium cacodylate buffer and 0.05 M sucrose.
Samples were then post-fixed in Karnovsky’s 0.5% OsO
 
4
 
/0.8%
K
 
3
 
Fe(CN)
 
6
 
, followed by 1% tannic acid. Cells were stained en
bloc in 1% uranyl acetate, dehydrated with ethanol, and embedded
in Spurr’s resin. Thin sections were cut with an RMC MT-7000
ultramicrotome, stained with 1% uranyl acetate and Reynold’s
lead citrate and observed at 80 kV on a transmission electron mi-
croscope (CM-10; Philips Electron Optics, Mahwah, NJ).
 
CD4
 
1
 
 T Cell Proliferation and Cytokine Assays.
 
CD4
 
1
 
 T cells
were isolated from the spleens of 3–5 chlamydial-infected mice or
DC-immunized mice using anti–L3T4-microbeads (Miltenyi
Biotec Inc., Auburn, CA) following the manufacturer’s instruc-
tions. Pooled CD4
 
1
 
 cells were cultured in triplicate in 96-well
plates (3 
 
3
 
 10
 
5
 
 cells/well) in DME (GIBCO BRL) supplemented
with 10% FCS, 50 
 
m
 
M 2-ME, 100 U/ml penicillin, 10 
 
m
 
g/ml
gentamicin, or in AIM V serum-free medium (GIBCO BRL)
supplemented with 2-ME and antibiotics. CD4
 
1
 
 cells isolated
from mice immunized with DC were cultured in serum-free me-
dia to avoid immunological recognition of serum-derived pro-
teins. DC or syngeneic splenocytes were used as APC. DC APC
were incubated with HK EB (ratio of 1:0.1–100) at 37
 
8
 
C for 1.5 h,
washed and incubated in IMDM-10 containing GM-CSF for 40 h
as described by Inaba et al. (34). Chlamydial-pulsed DC were ir-
radiated (3,000 Rad) and 3 
 
3
 
 10
 
4
 
 cells/well were added to CD4
 
1
 
cells. Splenocyte APC were incubated with HK EB (ratio of 1:5),
irradiated, washed, and then 5 
 
3
 
 10
 
5
 
 cells/well were added to
CD4
 
1
 
 cells. After 48 h incubation, supernatants (100 
 
m
 
l) were
collected for cytokine assays and cell proliferation was measured
by incorporation of [
 
3
 
H]thymidine (1 
 
m
 
Ci/well, 90 Ci/mmol;
DuPont-NEN, Boston, MA). Plates were pulsed overnight and
radioactivity determined using a TopCount NXT microplate
scintillation counter (Packard Instrument Company, Meriden,
CT). In some experiments CD4
 
1
 
 cells and APC were cultured in
1-ml aliquots at the cell concentrations described above and su-
pernatants were collected at 72 h for cytokine determination.
 
Flow Cytometry.
 
DC alone or DC that were inoculated with
HK EB and incubated at 37
 
8
 
C in IMDM-10 containing GM-
CSF for 40 h were stained with FITC-conjugated AF6-120.1
(anti-I-A
 
b
 
), GL1 (anti-CD86, B7-2), 3E2 (anti-CD54, ICAM-1),
or rat anti-CD80 (B7-1) followed by FITC-conjugated mouse 
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anti–rat antibodies (PharMingen, San Diego, CA). Staining was done
in PBS containing 5% FCS on ice for 20 min. Flow cytometry anal-
ysis was performed with a FACStar
 
Ò
 
 instrument (Becton Dickin-
son, San Jose, CA). Data were collected on 10,000 cells and dead
cells were excluded from analysis by propidium iodide staining.
 
Adoptive Immunization and Chlamydial Challenge.
 
DC were in-
cubated with medium or HK EB (ratio of 1:25) at 37
 
8
 
C for 1.5 h,
washed and incubated in IMDM-10 containing GM-CSF for 40 h.
The culture supernatants were collected at 24 h after inoculation
for cytokine assays. Chlamydial-pulsed DC were collected and
injected intravenously by infusion into the retro-orbital sinus of
mice at a concentration of 1 
 
3
 
 10
 
6
 
 cells/mouse in 0.2 ml PBS.
Mice were injected three times with DC at weekly intervals. 7 d
before chlamydial challenge mice were treated with Depo-Prov-
era (The Upjohn Company, Kalamazoo, MI) to synchronize es-
trous. Mice were challenged intravaginally with chlamydiae
(1,500 IFU) 14 d after the third immunization. Protection was as-
sessed by quantifying the number of IFU recovered from cervico-
vaginal swabs taken at different times after infection (13). Entire
genital tracts were removed from mice at 7 and 70 d after infec-
tion for histopathology (Histo-Path of America,
 
 
 
Millersville,
MD) and gross pathological evaluation for the presence of hydro-
salpinx, respectively.
 
Antibody and Cytokine ELISA.
 
Serum antibody titers of chla-
mydial-specific IgG1 and IgG2a were assayed by ELISA using for-
malin fixed MoPn EB and alkaline phosphatase-conjugated goat
anti–mouse IgG antibodies (Southern Biotechnology Associates, Bir-
mingham, AL) as described previously (12). All cytokines were mea-
sured by ELISA using corresponding specific capture and detection
antibodies and cytokine levels were calculated using standard curves
constructed using recombinant murine cytokines (PharMingen).
 
Results
 
Phagocytosis of Killed Chlamydiae by DC.
 
Chlamydial EB
were heat killed and their interactions with DC were studied
 
by fluorescent antibody staining and electron microscopy.
DC exposed to HK EB and stained with an antichlamydial
LPS mAb 24 h later exhibited intense fluorescent staining.
The majority of DC were positively stained and fluores-
cence appeared as a fine punctate pattern distributed
throughout the cytoplasm mixed with less frequent num-
bers of larger particulate staining structures (Fig. 1 
 
A
 
). Con-
trol uninoculated DC did not exhibit fluorescent staining
(data not shown). Examination of DC by electron micros-
copy 4 h after addition of HK EB showed intracellular or-
ganisms present in cytoplasmic vacuoles. Chlamydial EB
were visualized as 200–400-nm electron dense particles that
were present in the majority of DC examined. Chlamydial
EB were localized within tight membrane bound vacuoles
containing either single or multiple organisms (Fig. 1, 
 
B
 
 and
 
C
 
). These results demonstrate that DC phagocytose killed
chlamydiae, a finding recently described by Ojcius et al. (35).
 
Cytokine Secretion by DC.
 
IL-12 is an important cyto-
kine in driving the differentiation of precursor Th cells to a
Th1 phenotype (36, 37). Recent studies have shown that
DC, not macrophages, produce IL-12 in vivo upon micro-
bial stimulation (38). Therefore, it is important to deter-
mine if ingestion of chlamydial EB stimulated DC to pro-
duce IL-12. The supernatants from chlamydial-pulsed and
unpulsed DC were collected 24 h after inoculation and as-
sayed by ELISA for IL-12 p75, IL-12 p40, TNF-
 
a
 
,
 
 and IL-6.
Chlamydial-pulsed DC were found to secrete elevated lev-
els of the IL-12 p40 subunit and IL-6 (Fig. 2). Neither the
IL-12 p75 heterodimer nor TNF-
 
a
 
 was detectable by
ELISA in culture supernatants of chlamydial-pulsed DC.
Bioactive IL-12 p75 is composed of a constitutively ex-
pressed p35 subunit and an induced p40 subunit. The p40
subunit is expressed at levels 10–50 times greater than the
Figure 1. Dendritic cells ingest HK chlamydiae. (A) Fluorescent antibody staining of DC pulsed with HK EB. The majority of DC stain positive for
chlamydial antigen indicating that DC uniformly ingested HK chlamydial organisms. Fluorescence was visible as fine punctate and large aggregate parti-
cles in the same DC (A, right inset). Inset on the left shows a phase contrast photomicrograph of cultured DC. Note the characteristic large processes or
veils extending in many directions from the DC. (B and C) Electron micrographs of DC inoculated with HK chlamydial organisms for 4 h. Vacuoles
containing EB (arrows) were evident throughout the DC cytoplasm. EB were present in vesicles either individually or as aggregates. Bars: (A) 5 mm; (B
and C) 0.5 mm. 
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p75 heterodimer (39); this factor likely explains our inabil-
ity to detect p75. The inability to detect IL-12 p75 het-
erodimer has also been reported by others, and elevated
levels of p40 expression has been translated to reflect suffi-
cient levels of IL-12 p75 for in vivo bioactivity (38). The
expression of the adhesion molecule ICAM-1 and the
costimulatory molecules B7-1 and B7-2 on chlamydial-
pulsed DC was analyzed by FACS
 
Ò
 
. There was no upregu-
lation of these cell surface molecules after chlamydial inges-
tion by DC (data not shown).
 
Presentation of Chlamydial Antigen(s) to Infection Sensitized
CD4
 
1
 
 T Cells by Chlamydial-pulsed DC.
 
We next asked
whether chlamydial-pulsed DC could present processed
chlamydial antigen(s) to CD4
 
1
 
 T cells recovered from the
spleens of mice that had been previously infected and re-
solved chlamydial genital infection similar to those results
described by Ojcius et al. (35). These mice exhibit opti-
 
mum protective immunity to vaginal rechallenge and im-
mune CD41 T cells recovered from their spleens are pro-
tective after adoptive transfer to naive mice (13). The
proliferative response and cytokine secretion profiles of im-
mune CD41 T cells after incubation with chlamydial-
pulsed DC are shown in Fig. 3. Immune CD41 T cells
proliferated strongly in an antigen specific, dose-dependent
manner against chlamydial-pulsed DC (Fig. 3 A). Analysis
of cytokines secreted by immune CD41 T cells revealed
the expression of IFN-g and IL-10 with no detectable ex-
pression of IL-4 or IL-5 (Fig. 3 B). Splenic CD41 T cells
isolated from naive mice did not proliferate or secrete de-
tectable levels of cytokines after incubation with DC pulsed
with HK EB. These findings indicate that in vitro pulsed
DC present chlamydial antigen(s) in common with those
recognized during natural infection with chlamydiae, and
imply that chlamydial-pulsed DC might induce a similar
protective CD41 Th1 immune response in vivo.
Immune Response of Mice after Adoptive Transfer of Chlamyd-
ial-pulsed DC. To investigate whether chlamydial-pulsed
DC were capable of eliciting a chlamydial-specific CD41
Th1 immune response, chlamydial-pulsed DC or DC
alone were adoptively transferred to mice by intravenous
injection. After immunization, mouse sera were analyzed
by ELISA for anti-chlamydial IgG1 and IgG2a-specific an-
tibodies, and splenic CD41 T cells isolated from immu-
nized mice were assessed for antigen-specific cytokine pro-
duction (Fig. 4). The serum antibody and splenic CD41 T
cell responses of chlamydial-infected mice were assayed in
parallel and compared with mice immunized with chlamyd-
ial-pulsed DC. Chlamydial-specific serum antibodies of in-
fected and DC-immunized mice were predominately of
the IgG2a isotype with little to no detectable IgG1, an Ig
profile consistent with stimulation of type 1 immune re-
sponses (Fig. 4 A). Splenic CD41 T cells isolated from chla-
mydial-infected and antigen-pulsed DC-immunized mice
secreted IFN-g and IL-10 but not IL-4 or IL-5 (Fig. 4 B).
Thus, chlamydial-infected mice and mice immunized with
chlamydial-pulsed DC produced a strikingly similar Th1-
biased immune response as shown by the predominance of
IgG2a serum antibodies, and elevated levels of IFN-g pro-
duction by CD41 T cells.
Figure 2. Chlamydial-pulsed DC produce IL-12. DC were inoculated
with HK EB (filled bars), ratio 1:25, or medium alone (striped bars) at 378C
for 1.5 h, washed and incubated in IMDM-10 containing GM-CSF. The
culture supernatants were collected 24 h after inoculation with HK EB
and analyzed by ELISA for IL-12 p75, IL-12 p40, IL-6, and TNF-a.
Chlamydial-pulsed DC secreted elevated levels of IL-12 p40 and IL-6.
Neither IL-12 p75 nor TNF-a was detectable in the supernatants of
chlamydial-pulsed DC. Results are expressed as pg/ml 6 SD.
Figure 3. Chlamydial-pulsed
DC present antigen(s) to CD41
T cells isolated from chlamydial-
infected mice. (A) Proliferation
assay. (B) Cytokine assay. Splenic
CD41 T cells were isolated from
chlamydial-infected (filled bars) or
naive control mice (striped bars)
and incubated with irradiated
chlamydial-pulsed DC at 378C
for 48 h. CD41 T cell prolifera-
tion was measured by incorpora-
tion of [3H]thymidine and cy-
tokines secreted by CD41 T cells
assayed by ELISA. Data are pre-
sented as the mean of triplicate
samples 6 SD.813 Su et al.
Mice Adoptively Immunized with Chlamydial-pulsed DC Are
Protected against Chlamydial Genital Tract Infection. To ascer-
tain if the immune response produced by mice immunized
with chlamydial-pulsed DC was protective, vaccinated ani-
mals were challenged intravaginally with chlamydiae and
protection was assessed by (a) quantifying the numbers of
infectious chlamydiae recovered from the vaginas of mice,
(b) evaluating the inflammatory response present in genital
tissue by routine histopathological examination, and (c)
monitoring the development of hydrosalpinx by gross ex-
amination. Naive mice and mice immunized with equiva-
lent numbers of DC or HK EB alone were similarly chal-
lenged and evaluated. The magnitude of protection
conferred to mice by adoptively transferred chlamydial-
pulsed DC was compared with the level of immunity ex-
hibited by previously infected mice. Immunity after infec-
tion with live organisms is highly protective in this model.
Mice adoptively immunized with chlamydial-pulsed DC
shed 2.91 logs less infectious organisms than naive control
mice after intravaginal challenge (Fig. 5). This level of pro-
tection was equivalent to that observed in the previously
infected group that shed 3.13 logs less organisms than con-
trols. Immunization with equivalent numbers of control
DC or HK EB was not protective.
Disease was assessed by histopathological evaluation of
genital tract tissue and scoring for the development of hy-
drosalpinx by gross examination in chlamydial challenged
mice. Fig. 6 shows a representative example of hematoxy-
lin- and eosin-stained uterine tissue from mice immunized
with DC alone or DC pulsed with HK EB. Sections of the
reproductive tract of the DC-immunized mice revealed in-
tense inflammatory infiltrates from the ectocervix to the
oviducts. The infiltrates, consisting primarily of PMN with
scattered mononuclear cells, were observed from serosal to
mucosal surfaces, but were most concentrated at the mu-
cosa. The lumen of the uterine horns were engorged with
purulent exudate (Fig. 6 A) and more distally, intraepithe-
lial PMN were abundant (Fig. 6 C), often associated with
destruction of the endometrial lining. The stroma of the
endometrium exhibited vascular congestion, was hypercel-
lular and contained scattered PMN. In contrast, the repro-
ductive tracts of mice immunized with DC pulsed with
HK EB were normal or showed mild inflammatory reac-
tions. Fig. 6 B shows the stained uterine tissue of a culture
Figure 4. Mice immunized
with chlamydial-pulsed DC pro-
duce a CD41 Th1 immune re-
sponse. (A) IgG1 and IgG2a
chlamydial-specific antibody re-
sponses in the sera of mice im-
munized with chlamydial-
pulsed DC or infected with
chlamydiae. Mice were bled 7 d
after the third immunization
with DC or 35 d after intravagi-
nal infection and serum antibody
responses were assayed by ELISA
against formalin fixed C. tracho-
matis MoPn EB. Five mice per
group were analyzed and sera
were tested individually. Results
are expressed as the mean OD 6
SD. (B) Antigen-specific CD41 T cell cytokine secretion profiles of mice immunized with chlamydial-pulsed DC or infected with chlamydiae. CD41 T
cells were obtained from the spleens of mice 6 d after a primary immunization with DC (dotted bars), DC pulsed with HK EB (striped bars), or 35 d after
infection (filled bars), and then cultured in serum-free medium with syngeneic chlamydial-pulsed splenocytes as APC. Culture supernatants were collected
72 h after incubation for cytokine assays. Cytokine results are expressed as pg/ml 6 SD.
Figure 5. Mice immunized with chlamydial-pulsed DC are protected
against chlamydial infection of the genital tract. Naive mice, mice immu-
nized with DC pulsed with HK EB, DC alone, or HK EB alone, or mice
that had previously been infected with chlamydiae were challenged intra-
vaginally with 1,500 IFU of C. trachomatis MoPn EB. The results shown
are from two different experiments and the circles represent culture results
from individual mice. The solid circles are results from experiment 1, and
the open circles from experiment 2. All mice were cultured at 5 d after
challenge and protective immunity was monitored by quantifying the
number of chlamydial IFU recovered from cervicovaginal swabs. Naive
mice and mice immunized with equivalent numbers of DC or HK EB
alone served as negative controls. Mice that had been previously infected
genitally and had resolved their primary infection (45 d after infection)
served as positive controls. Note that mice immunized with DC pulsed
with HK EB were equally as immune as mice previously infected geni-
tally, both groups shedding z3 logs less chlamydiae than the naive control
group. In contrast, mice immunized with equivalent numbers of DC or
HK EB alone were not protected. Infected mice and mice immunized
with DC pulsed with HK EB cleared infection by day 10 after challenge
whereas the remaining groups cleared infection between 21 and 28 d after
challenge.814 Vaccination against Chlamydia Using Ex Vivo Antigen-pulsed DC
negative mouse immunized with DC pulsed with HK EB.
The folds of endometrium were readily recognized, the lu-
men of the uterus clear, and the endometrial stroma ar-
ranged in loose networks of cells. Under high magnifica-
tion the epithelium of the endometrium exhibited a
uniform arrangement of nuclei at the basal aspect of the
cells (Fig. 6 D) which contrasts with the disordered ar-
rangement seen in the DC mice (Fig. 6 C). In the case of
the mice that shed low numbers of infectious chlamydiae
the inflammatory infiltrates were mild and similar in char-
acter to those observed in unprotected mice.
Hydrosalpinx is a common sequelae of chlamydial geni-
tal tract infection in the mouse model that develops due to
a consequence of inflammatory infiltrates in the walls of the
oviducts leading to scarring and obstruction of fluid flow
(8–10). This is the most important sequelae of chlamydial
STD because it leads to infertility, which is generally not
amenable to surgical correction (10). Therefore, it was im-
portant to ascertain whether immunization with chlamyd-
ial-pulsed DC prevented the development of hydrosalpinx.
The incidence of hydrosalpinx in DC-immunized and
control mice is shown in Fig. 7. 80% (4/5) of naive control
mice and 62% (5/8) of mice immunized with DC alone
exhibited hydrosalpinx after chlamydial infection. In con-
trast, none (0/5) of the mice immunized with chlamydial-
pulsed DC developed hydrosalpinx. Collectively, these
results demonstrate that immunization with chlamydial-
pulsed DC induced a highly significant level of protective
immunity against chlamydial infection. Immunization reduced
the infectious burden of chlamydiae shed from genital tissue
to levels equivalent to that obtained from previously in-
fected mice, and prevented genital tract inflammatory dis-
ease and its obstructive sequelae.
Discussion
We have shown that adoptively transferred DC pulsed
ex vivo with HK chlamydiae elicit a chlamydial-specific
CD41 Th1-biased immune response in vivo that confers a
level of protective immunity against infection of the female
Figure 6. Histopathology of genital tract tissues of mice immunized with chlamydial-pulsed DC. A comparison of hematoxylin- and eosin-stained sec-
tions of the wall of the uterus from a DC-immunized mouse (A and C) and a mouse immunized with DC pulsed with HK EB 7 d after challenge (B and
D). Note the difficulty distinguishing the border of the endometrial folds (A, arrows point to the epithelial layer). This is due to the lumen (*) of the
uterus being engorged with inflammatory exudate. PMN can be seen within the stroma (S) of the endometrium as well as within the epithelial layer (C,
arrow) and the nuclei of the epithelial cells are disordered. This picture contrasts dramatically with the mouse immunized with chlamydial-pulsed DC in
which the endometrial folds are distinct, the lumen (*) empty, the stroma (S) arranged in a loose network (B) and the nuclei of the epithelial layer ori-
ented at the basal aspect of the cells (D). The results shown are representative of stained sections from three mice of each experimental group. Magnifica-
tion: (A and B) 303; (C and D) 1253.815 Su et al.
genital tract equivalent to that produced by infection. Pro-
tection was demonstrated by z3 logs fewer infectious
chlamydiae shed from the cervicovagina of vaccinated
mice, minimal to no inflammatory response in genital tract
tissue, and prevention of hydrosalpinx. These studies are
the first to describe the development of a highly efficacious
vaccine against chlamydial infection of the genitourinary
tract despite nearly a decade of effort. The observation that
ex vivo antigen-pulsed DC are effective mediators of pro-
tective tumor immunity is well documented (25–31); how-
ever, we are aware of only one report using pulsed DC to
adoptively immunize against infectious diseases (40), and
no reports demonstrating the use of this approach to pro-
tect against mucosal pathogens that infect the genitourinary
tract. Inaba et al. (34) described that DC pulsed with Myco-
bacteria in vitro induced a strong T cell response in vivo to
mycobacterial antigens; but infectious challenge experi-
ments were not performed by these investigators. More re-
cently, investigators have suggested ex vivo antigen-pulsed
DC could be potentially useful for adoptive transfer immu-
notherapies to vaccinate against infectious agents (22, 33,
41), including chlamydiae (35), but direct evidence using
in vivo infection models were not described. The findings
reported in this work have experimentally tested and
proven this hypothesis in a preclinical animal model of im-
munity and infection.
Chlamydia (15) and other intracellular parasites, such as
Mycobacteria (42), Listeria (43), Leishmania (44), and Toxo-
plasma (45) elicit IL-12–dependent CD41 Th1 responses
after infection that have been shown to be important in the
generation of protective immunity to infection. A common
goal and continuous challenge for investigators studying
these pathogens has been the development of immuniza-
tion strategies capable of producing CD41 Th1 protective
immunity. Successful results towards this end have been re-
cently described after coimmunization with Leishmania (46)
or Listeria (47, 48) antigens and exogenous IL-12. In those
studies potent antiparasite Th1 immunity was elicited and
high levels of protective efficacy achieved. We have used
this same strategy in attempts to generate protective Th1
antichlamydial immunity. Mice immunized intraperito-
neally with HK EB plus IL-12 generated a strong chlamy-
dial-specific Th1 immune response; however, they were
not protected after chlamydial genital tract challenge (un-
published observations). The reason this approach was un-
successful for preventing chlamydial infection is likely due
to differences in the host cells infected by Chlamydia and
these other intracellular parasites. Chlamydial infection is
restricted to epithelial cells of the genital tract whereas Lis-
teria and Leishmania organisms infect macrophages in the
spleen and subcutaneous tissue of the foot pad, respectively.
Interestingly, immunization with chlamydial-pulsed DC or
HK EB plus exogenous IL-12 both induced Th1 immune
responses, but importantly, only chlamydial-pulsed DC
elicited immunity capable of protecting against infection of
the genital tract. DC possess multiple properties that pro-
mote Th1 immune responses including their high level of
MHC class II expression, secretion of the Th1-polarizing
cytokine IL-12, and homing properties that direct migra-
tion to the parafollicular areas of lymphatic tissue where
they interdigitate between T cells (22, 23, 37, 49–51). The
capabilities of antigen-pulsed DC to migrate to regional or
mucosal lymphoid tissue may be the key to their ability to
activate and drive differentiation of chlamydial-specific
Th1 cells that are capable of homing to the genital mucosa.
These T cell populations may not be sufficiently sensitized
after parenteral immunization with HK EB and exogenous
IL-12, which could explain the ineffectiveness of this im-
munizing strategy for the prevention of chlamydial infec-
tion of the genital tract. It will be important to use this
model to define the migration patterns of adoptively trans-
ferred DC that allow them to induce mucosal protective
immunity and to identify components that mediate DC
homing. These studies may provide important clues for the
design of conventional vaccines capable of targeting pro-
tective T cell immunity at the genital mucosa.
At present it would be impractical to suggest the use of
autologous ex vivo antigen-pulsed DC as immunotherapies
for the prevention of chlamydial infections of humans.
Nevertheless, the results described herein clearly demon-
strate the feasibility of producing a highly efficacious vac-
cine against chlamydial infection of the genital tract using
nonviable organisms. This is an important finding since
previous immunization studies using this model have
shown that optimum protective immunity against chlamyd-
ial genital infection could only be produced using viable
organisms (20, 21) although significant levels of protection
against infertility have been described after immunization
of mice with chlamydial outer membrane complexes (52).
These findings have led to the conclusion that a vaccine ef-
fective against chlamydial genital tract infection can only be
attained using live attenuated organisms. The work re-
Figure 7. Incidence of hydrosalpinx in mice immunized with chlamyd-
ial-pulsed DC. Naive and DC-immunized groups of mice were killed
70 d after intravaginal chlamydial challenge and scored for the presence or
absence of hydrosalpinx. Hydrosalpinx is a common sequelae of infection
in this model and results from occlusion of the oviduct. Mice suffering
hydrosalpinx are infertile. The numbers above the columns correspond to
the number of mice used for each of the experimental groups. The DC
pulsed with HK EB immunized group is significantly different than the
naive control group (P , 0.05, two-tailed Fisher’s exact test).816 Vaccination against Chlamydia Using Ex Vivo Antigen-pulsed DC
ported here argues strongly against this hypothesis and
demonstrates that antigens capable of eliciting protective
cellular immunity are present on intact nonreplicating
chlamydiae. Thus, it should be possible to develop an effi-
cacious chlamydial vaccine using conventional approaches.
To reach this goal it will be important to understand the
immunizing property(s) of chlamydial-pulsed DC that con-
fer protective Th1-mediated immunity mucosally, and to
identify chlamydial protective antigens that can be used for
immunological targeting and vaccine development. The
DC system described here represents a powerful means to
identify chlamydial protective antigens through reconstitu-
tion experiments. For example, DC pulsed ex vivo with
acellular or recombinant antigens, or transfected with DNA
encoding antigen(s) can be used to efficiently target anti-
chlamydial immunity at the genital mucosa.
DC pulsed ex vivo with inactivated pathogens are theo-
retically capable of independently inducing multi-faceted
immune responses that include antibodies, CD41 and
CD81 T cell–mediated cellular immunity against a broad
range of antigens expressed by a pathogen. This powerful
targeted approach to immunization, coupled with the abil-
ity of DC to elicit functional mucosal immunity after
parenteral immunization, has obvious advantages for the
development of vaccines to control other infectious agents.
Adoptive immunization with ex vivo antigen-pulsed DC
may be particularly applicable in vaccine development
against infectious diseases that constitute more severe health
risks to humans. An example where such an approach
might be considered is in the design of immunotherapeutic
strategies against HIV, a disease that would justify both an
unconventional and aggressive approach to vaccination. In
support of this idea is the recent observation that HIV-spe-
cific CD41 responses are strongly associated with the control
of viremia (53). Thus, the use of HIV or antigen-pulsed au-
tologous DC might be a means of efficiently stimulating
vigorous anti-HIV CD41 immunity.
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